Literature DB >> 10520838

Eradication of Helicobacter pylori normalizes elevated mucosal levels of epidermal growth factor and its receptor.

W J Coyle1, R E Sedlack, R Nemec, R Peterson, T Duntemann, M Murphy, J M Lawson.   

Abstract

OBJECTIVE: Helicobacter pylori (H. pylori) infection has been linked to gastric cancer. The factors that promote carcinogenesis remain unknown. Epidermal growth factor (EGF) has been shown to be a potent epithelial mitogen and oncoprotein when sustained over expression occurs. Our aim was to compare gastric mucosal levels of EGF and its receptor (EGFR) among controls, H. pylori infected subjects, and subjects following H. pylori eradication using quantitative flow cytometric analysis.
METHODS: Patients referred for evaluation of dyspepsia underwent EGD and six antral biopsies were performed (two each for rapid urease testing (RUT), histopathology, and flow cytometry). Controls were those found to be H. pylori negative while subjects had confirmed infection. The study patients were treated, then had repeat EGD with biopsies.
RESULTS: There were 17 controls and 28 cases. Mean EGF and EGFR values were 2.69 and 2.46 for controls and 4.67 and 4.64 for subjects. Subjects' mean EGF was 73% higher (p = .035) and EGFR was 88% higher (p = 0.029) than controls. After treatment, the subjects' mean values declined 55% (p = 0.0001) for EGF and 40% (p = 0.002) for EGFR. Three subjects had persistent infection and showed no change in their EGF/EGFR levels. No difference was found among factor levels with respect to endoscopic findings.
CONCLUSIONS: Both EGF and EGFR from gastric antral biopsies are increased nearly 2-fold in infection with H. pylori. Infection eradication reduces levels of both factors to those of controls. One major pathogenic mechanism for gastric mucosal hyperproliferation and possibly carcinogenesis related to H. pylori may be the over expression of EGF and increased receptor density of EGFR on gastric mucosal cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520838     DOI: 10.1111/j.1572-0241.1999.01432.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

Review 1.  Signal transduction of Helicobacter pylori during interaction with host cell protein receptors of epithelial and immune cells.

Authors:  Suneesh Kumar Pachathundikandi; Nicole Tegtmeyer; Steffen Backert
Journal:  Gut Microbes       Date:  2013-11-06

2.  Effect of Helicobacter pylori infection on epidermal growth factor receptor (EGFR) expression and cell proliferation of gastric epithelial mucosa: correlation to macroscopic and microscopic diagnosis.

Authors:  Agnes Ruzsovics; Zsuzsa Unger; Bela Molnar; Laszlo Pronai; Zsolt Tulassay
Journal:  Int J Exp Pathol       Date:  2002-10       Impact factor: 1.925

Review 3.  Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients.

Authors:  Devron R Shah; Shamik Dholakia; Rashmi R Shah
Journal:  Drug Saf       Date:  2014-03       Impact factor: 5.606

4.  Possible involvement of leptin and leptin receptor in developing gastric adenocarcinoma.

Authors:  Liang Zhao; Zhi-Xiang Shen; He-Sheng Luo; Lei Shen
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

5.  MicroRNA-206 suppresses gastric cancer cell growth and metastasis.

Authors:  Jun Ren; Hui-Jie Huang; Yu Gong; Shen Yue; Li-Ming Tang; Steven Y Cheng
Journal:  Cell Biosci       Date:  2014-05-05       Impact factor: 7.133

Review 6.  Type IV Secretion and Signal Transduction of Helicobacter pylori CagA through Interactions with Host Cell Receptors.

Authors:  Steffen Backert; Nicole Tegtmeyer
Journal:  Toxins (Basel)       Date:  2017-03-24       Impact factor: 4.546

Review 7.  Tyrosine Kinases in Helicobacter pylori Infections and Gastric Cancer.

Authors:  Bianca E Chichirau; Sebastian Diechler; Gernot Posselt; Silja Wessler
Journal:  Toxins (Basel)       Date:  2019-10-11       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.